"Notable breakthrough" With the discovery of a breast cancer drug that shrinks tumors and saves thousands of lives!

INA-  sources


Experts say up to 8,000 cancer patients in the UK could receive a revolutionary drug that has been proven to shrink tumors and slow the progression of the disease.

A 700-person trial produced “remarkable” results after it was shown that the drug could double the time it takes for the disease to develop. Both patients with advanced and more advanced breast cancer may benefit from treatment when taken along with hormone therapy.
The results of the phase III clinical trial were presented at the Breast Cancer Symposium in San Antonio on Thursday.

In the study, 355 patients received the drug along with fulvestrant, a common hormonal agent given to patients with advanced disease.
Capivarsertib appears to complement hormone therapy by inhibiting the activity of the cancer-causing protein molecule AKT.

The researchers found that the drug, combined with hormone therapy, reduced tumors in 23% of patients, compared with 12% in those who received a placebo.
Another important finding was that the time to disease progression in these patients increased from 3.6 to 7.2 months.
Professor Christian Helin, Executive Director of ICR, said: “This is a historic moment for the treatment of advanced forms of the most common type of breast cancer. Capivasertib may offer an entirely new treatment option for these patients. This is a huge success. a story for British science when the discovery and development of capivasertib demonstrated the benefits of collaboration between academia, philanthropic organizations and industry to bring new, revolutionary treatments to people with cancer as quickly as possible.”
In the study, 355 additional patients received combination treatment with fulvestrant and placebo.
This helped prove that the new treatment regimen is more effective in patients with mutations in their AKT signaling pathways.
In this group, 29% of the tumor was reduced, compared with 10% in the placebo group.
He added: “Even with the best current treatments, people with this advanced form of breast cancer will eventually see their cancer stop responding to treatment and progress. We are excited that this potential first-of-its-kind drug is combined with hormone therapy can slow the progression of these advanced cancers.” “In about a third of cases, it can shrink the size of the tumor. We think this new treatment could allow more women and men to live well and longer with breast cancer.”
The drug is currently being manufactured by AstraZeneca following the completion of a drug discovery research program at the Institute for Cancer Research (ICR) in London.

source: asumetech